Research programme: protein arginine methyltransferase 5 inhibitors- Cancer Therapeutics/ MerckAlternative Names: PRMT5 program; protein arginine methyltransferase 5 program
Latest Information Update: 20 Jul 2016
At a glance
- Originator Cancer Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein methyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Haematological disorders